Overview of Dr. Kuykendall
Dr. Andrew Kuykendall is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. He received his medical degree from University of Florida College of Medicine and has been in practice 5 years. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 50 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. He has more than 80 publications and over 500 citings.
Office
12902 Magnolia Drive
Tampa, FL 33612
Education & Training
- University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2015 - 2018
- University of South Florida MorsaniResidency, Internal Medicine, 2012 - 2015
- University of Florida College of MedicineClass of 2012
Certifications & Licensure
- FL State Medical License 2014 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 10 citationsPTPN11 mutations are associated with poor outcomes across myeloid malignancies.David M Swoboda, Najla Al Ali, Onyee Chan, Eric Padron, Andrew T. Kuykendall
Leukemia. 2021-01-01 - 6 citationsMYC overexpression is associated with an early disease progression from MDS to AML.David Gajzer, Constantine Logothetis, David A. Sallman, Gregoire Calon, Abida Babu
Leukemia Research. 2021-12-01 - 10 citationsMolecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, Wassim Samra, Justin M Watts
Cancer. 2022-11-01
Abstracts/Posters
- Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell TransplantationAndrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center DatabaseAndrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical StateAndrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
- Systemic Mastocytosis: Information for Patients and CaregiversAugust 26th, 2024
- Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK InhibitorDecember 1st, 2022
- Four of a Kind?May 1st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: